"Multi-Target Drug Blocks Myeloma Proliferation"
Preclinical studies have shown that a novel dual kinase inhibitor blocks key oncogenic pathways in multiple myeloma cell lines, and also in primary multiple myeloma cells taken from patients with refractory disease. "Numerous CDK inhibitors with differing mechanistic profiles are currently being preclinically and clinically evaluated but have not as of yet resulted in a drug approval mainly because of lack of selectivity and high toxicity," wrote Deepak Perumal, PHD, a post-doctoral research at the Icahn School of Medicine at Mount Sinai, and colleagues. "Our data provides the foundation for further development." Learn more.
Mount Sinai Public Health Expert Joins ‘Call to Action’ on Gun Safety
Jan 19, 2017 View All Press ReleasesMultiVu - "Philips Receives CE Mark for First New Imaging Modality in 10 Years"
Jan 25, 2011 View All Press Releases